Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Didier TronoAfter obtaining an M.D. from the University of Geneva and completing a clinical training in pathology, internal medicine and infectious diseases in Geneva and at Massachusetts General Hospital in Boston, Didier Trono embarked in a scientific career at the Whitehead Institute for Biomedical Research of MIT. In 1990, he joined the faculty of the Salk Institute for Biological Studies to launch a center for AIDS research. He moved back to Europe seven years later, before taking the reins of the newly created EPFL School of Life Sciences, which he directed from 2004 to 2012. He is now actively engaged in the efforts of Switzerland to integrate new technologies in the fields of precision medicine and personalized health.
Vassily HatzimanikatisDr. Vassily Hatzimanikatis is currently Associate Professor of Chemical Engineering and Bioengineering at Ecole Polytechnique Federale de Lausanne (EPFL), in Lausanne, Switzerland. Vassily received a PhD and an MS in Chemical Engineering from the California Institute of Technology, and his Diploma in Chemical Engineering from the University of Patras, in Greece. After the completion of his doctoral studies, he held a research group leader position at the Swiss Federal Institute of Technology in Zurich (ETHZ), Switzerland. Prior to joining EPFL, Vassily worked for three years in DuPont, Cargill, and Cargill Dow, and he has been assistant professor at Northwestern University, at Illinois, USA.
Vassilys research interests are in the areas of computational systems biology, biotechnology, and complexity. He is associate editor of the journals Biotechnology & Bioengineering, Metabolic Engineering and Integrative Biology, and he serves on the editorial advisory board of the journals Bioprocess and Biosystems Engineering, Journal of Chemical Technology and Biotechnology, and Industrial Biotechnology. He has written over 70 technical publications and he is co-inventor in three patents and patent applications.
Vassily is a fellow of the American Institute for Medical and Biological Engineering (2010), he was a DuPont Young Professor (2001-2004), and he has also received the Jay Bailey Young Investigator Award in Metabolic Engineering (2000), and the ACS Elmar Gaden Award (2011).
Olivier SchneiderAfter his thesis defense in particle physics in 1989 at University of Lausanne, Olivier Schneider joins LBL, the Lawrence Berkeley Laboratory (California), to work on the CDF experiment at the Tevatron in Fermilab (Illinois), first as a research fellow supported by the Swiss National Science Foundation, and later as a post-doc at LBL. He participates in the construction and commissioning of the first silicon vertex detector to operate successfully at a hadron collider; this detector enabled the discovery of the sixth quark, named "top". Since 1994, he comes back to Europe and participates in the ALEPH experiment at CERN's Large Electron-Positron Collider, as CERN fellow and then as CERN scientific staff. He specializes in heavy flavour physics. In 1998, he becomes associate professor at University of Lausanne, then extraordinary professor at the Swiss Institute of Technology Lausanne (EPFL) in 2003, and finally full professor at EPFL in 2010. Having worked since 1997 on the preparation of the LHCb experiment at CERN's Large Hadron Collider, which started operation in 2009, he is now analyzing the first data. He also contributes since 2001 to the exploitation of the data recorded at the Belle experiment (KEK laboratory, Tsukuba, Japan). These two experiments study mainly the decays of hadrons containing a b quark, as well CP violation, i.e. the non-invariance under the symmetry between matter and antimatter.
Jacques FellayJacques Fellay is a medical scientist with expertise in infectious diseases and human genomics. He obtained his MD from the University of Lausanne in 2002 and his PhD from University of Utrecht. After a clinical training in infectious diseases in Switzerland and a 4-years postdoctoral fellowship at Duke University, he joined the EPFL in April 2011 with an SNF Professorship.
On top of his EPFL affiliation, Jacques is also Head of Precision Medicine at the University Hospital (CHUV) in Lausanne, Group Leader at the Swiss Institute of Bioinformatics, and Co-director of the Health2030 Genome Center at Campus Biotech in Geneva.
Aurelio BayAurelio Bay graduated in physics at the University of Lausanne (UNIL) in 1980 and got his PhD degree from the same institution in 1986 for a work on the determination of the axial form factor of the ? meson.
He then went to Lawrence Berkeley Laboratories (LBL), USA as a post doc for two years, where he worked on the TPC/2? Electromagnetic Calorimeter and the SSC/LHC detector. He then came back to Europe and was named Maître Assistant at University of Geneva till 1994, where he started working at the L3 experiment of LEP at CERN.
He was appointed Assistant Professor at the University of Lausanne in 1994 and Full Professor in 1998, continuing working at LEP, LEP2 and LHCb at CERN , and starting a collaboration at BELLE experiment at KEK, Tsukuba (Japan).
At the University of Lausanne he was Director of the Institute of High Energy Physics, Deputy Director of the Physics Department and Deputy of the Dean of the Faculty of Sciences.
In 2003, following the merge of UNIL physics department into the EPFL School of Basic Sciences, he was appointed Full Professor at Ecole Polytechnique Fédérale de Lausanne (EPFL), and Director of the EPFL Laboratory of High Energy Physics.
Denis DubouleDenis Duboule is born in 1955 and is both swiss and french national. He studied biology at the university of Geneva, where he obtained a PhD in mammalian embryology in 1984. He then spent 10 years abroad, first as a group leader in the medical faculty in Strasbourg (France), then at the European Laboratory for Molecular Biology (EMBL) in Germany. In 1993, he was appointed full professor at the university of Geneva, where he chairs the department of Genetics and Evolution ever since 1997. In 2001, he chaired the national center of research Frontiers in Genetics and in 2012 the division III of the SNSF. In 2006, he was appointed full professor at the federal institute of technology (EPFL) in Lausanne, where he leads the laboratory of Developmental Genomics (UpDUB).
His research activities are in the fields of embryology, genetics and developmental genomics of mammals, in an evolutionnary context. In particular, his laboratory has been closely associated with the structural and functional studies of mammalian Hox genes, by using mouse molecular genetic approaches. Duboule is also active in the communication of science, is member of the Academia Europea as well as of several academies in Switzerland, France and the Netherland. He is a foreign member of the Royal Society (UK) and of the National Academy of Sciences USA. He has received various scientific prizes and awards, amongst which the Marcel Benoist Prize, the Louis-Jeantet prize for medicine in 1998 or the international INSERM prize in 2010 (see also https://en.wikipedia.org/wiki/Denis_Duboule). 